The study was stopped due to business/operational issues.

The purpose of this study is to assess the long term (up to 2 years) safety and tolerability of [S,S]-Reboxetine in patients with pain after shingles.

Inclusion Criteria:

• Patients must have pain present for more than 3 months after healing of the shingles skin rash.
• Patients at screening must have a score of >/=40mm on the pain visual analogue scale.

Exclusion Criteria:

• Patients with significant hepatic impairment.
• Patients with other severe pain, that may impair the self-assessment of pain due to postherpetic neuralgia (pain after shingles).